
Just under a year after MC2 Therapeutics received approval from the FDA for its psoriasis cream Wynzora, the treatment has been launched on the US market, the company reports in a press release.
The launch has been planned in collaboration with partner Epi Health, which specializes in dermatology, though MC2 has been working to establish itself as an independent company in the US.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app